Data di Pubblicazione:
2012
Abstract:
Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).
Tipologia CRIS:
03B-Review in Rivista / Rassegna della Lett. in Riv. / Nota Critica
Elenco autori:
Bardelli A; Jänne PA
Link alla scheda completa:
Pubblicato in: